Expression of Vasoactive Intestinal Peptide and Related Receptors in Overcirculation-Induced Pulmonary Hypertension in Piglets

被引:0
作者
Aline Vuckovic
Benoît Rondelet
Jean-Pierre Brion
Robert Naeije
机构
[1] Laboratory of Physiology and Physiopathology,
[2] Université Libre de Bruxelles,undefined
[3] Laboratory of Histology,undefined
[4] Neuroanatomy,undefined
[5] and Neuropathology,undefined
[6] Université Libre de Bruxelles,undefined
来源
Pediatric Research | 2009年 / 66卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The pathobiology of pulmonary arterial hypertension (PAH) is not understood completely. Recent observations in patients with PAH and in knockout models have raised the idea that a defect in vasoactive intestinal peptide (VIP) may be involved in PAH physiopathology. Therefore, we investigated the expressions of VIP, the related pituitary adenylate cyclase–activating polypeptide (PACAP), and their receptors (VPAC1, VPAC2, and PAC1) in piglets with overcirculation-induced pulmonary hypertension as an early-stage PAH model. Seventeen piglets were randomized to an anastomosis between the innominate and the main pulmonary artery, or to a sham operation. After 3 mo, a hemodynamic evaluation was performed and the lung tissue was sampled for biologic and histologic studies. The shunting increased pulmonary vascular resistance (PVR) by 100% and arteriolar medial thickness by 85%. VIP and VPAC1 gene expressions were decreased and increased, respectively. VPAC1 gene expression was positively correlated to PVR. VPAC2 and PAC1 immunoreactivity was seen in pulmonary arterial smooth muscle. VIP and PACAP immunostaining was observed in nerve fibers surrounding the pulmonary arterial smooth muscle. In conclusion, overcirculation-induced pulmonary hypertension is accompanied by a down-regulation of VIP signaling, without change in PACAP expression. These results are consistent with the notion that abnormal VIP signaling takes part in PAH pathogenesis.
引用
收藏
页码:395 / 399
页数:4
相关论文
共 151 条
  • [1] Farber HW(2004)Pulmonary arterial hypertension N Engl J Med 351 1655-1665
  • [2] Loscalzo J(2000)Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions Pharmacol Rev 52 269-324
  • [3] Vaudry D(2001)Vasoactive intestinal peptide: cardiovascular effects Cardiovasc Res 49 27-37
  • [4] Gonzalez BJ(2003)Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J Clin Invest 111 1339-1346
  • [5] Basille M(2008)Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung Exp Physiol 93 1210-1219
  • [6] Yon L(1988)Vasoactive intestinal peptide prevents increase in pulmonary artery pressure during hypoxia in newborn lambs Ann N Y Acad Sci 527 686-687
  • [7] Fournier A(1984)VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF) Peptides 5 325-328
  • [8] Vaudry H(1992)Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat J Appl Physiol 72 1212-1217
  • [9] Henning RJ(2007)Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene Circulation 115 1260-1268
  • [10] Sawmiller DR(2004)Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice Circulation 110 3245-3251